A Bid to Return Cold Medicine to Pharmacy Shelves
Reckitt Benckiser has officially petitioned New Zealand drug regulator Medsafe to remove pseudoephedrine from its status behind the pharmacy counter. The company aims to restore consumer access by allowing customers to select small, one-day packs directly from store shelves, similar to how they currently purchase paracetamol or ibuprofen. Despite this proposed shift, the medication would remain available exclusively within pharmacies to maintain some level of control over distribution.
This move represents a direct challenge to existing regulations that treat the drug as a restricted substance. Pharmacists currently act as gatekeepers for every purchase, evaluating the individual needs of a customer before dispensing the medicine. Reckitt Benckiser argues that the current system imposes an unnecessary burden on pharmacy staff while preventing patients from getting effective relief for common cold and flu symptoms.
Shifting Contexts of Methamphetamine Production
The central logic for the initial restriction of pseudoephedrine dates back to 2011, when it was classified as a prescription-only drug. At the time, legislators viewed the medicine as a primary component for illicit methamphetamine production. Criminals frequently used small-scale purchases from pharmacies to gather the necessary precursors for cooking the drug, known locally as P.
But the landscape for methamphetamine production has changed significantly in the last fifteen years. Reckitt Benckiser stated in its application that small-scale local production is no longer the primary driver of the market. Criminal organizations now rely on bulk importation of finished product or massive shipments of raw chemicals from overseas. The application asserts that restricting pharmacy sales of cold medicine does little to stop the current drug trade, as the focus of criminal groups has moved away from pharmacies entirely.
Regulatory History and Future Challenges
New Zealand's approach to this specific medicine has seen several reversals. After the strict 2011 crackdown, many manufacturers turned to phenylephrine as a substitute decongestant. That ingredient is now the focus of a class action lawsuit based on clinical data suggesting it does not work as advertised. The desire to provide a proven, effective alternative is a major driver behind this new proposal.
In 2024, the government reclassified pseudoephedrine from prescription-only to restricted status, fulfilling an election promise led by Act’s David Seymour. This change was a first step toward loosening controls that many industry observers viewed as outdated. If Medsafe approves this new application, it would mark a full return to open-shelf availability for specific product sizes.
Next Steps and Industry Implications
Medsafe’s Medicines Classification Committee has scheduled a review of the Reckitt Benckiser application for next month. Public interest in the case remains high, and the regulator has opened the door for community submissions until October 5. This feedback will shape the final decision on whether the restrictive barrier can be removed safely.
If the application proceeds, it may trigger a wider review of how other common medicines are classified in New Zealand. The broader significance lies in balancing public health access against historical security concerns. As the drug market continues to evolve toward large-scale international smuggling, regulators must decide if the costs of restricting common medicines still outweigh the benefits to patients. Observers should monitor the upcoming committee meeting to see if the current evidence on methamphetamine production trends holds enough weight to force a policy shift.